• Contact
  • OmniSeq Connect Portal
OmniSeq
  • Clinical Testing
    • OmniSeq INSIGHT
    • Order Test
    • Specimen Requirements
  • BioPharma Services
  • Publications
  • Patient Support
    • CARES Program
    • Frequently Asked Questions
  • About
    • About
    • Leadership
    • Careers
    • News
    • Forms
    • Contact
Select Page

Labcorp and OnmiSeq Launch Insight, Next-Generation Sequencing Platform to Advance Precision Oncology

by Christina Black | Jun 10, 2021 | News

OmniSeq Receives New York State Approval for Cancer Genomic, Immune Profiling Test

by Christina Black | Apr 27, 2021 | News

Cancer-testis antigen detection by targeted RNA sequencing

by OmniSeq Staff | Dec 3, 2020 | News

Abstract Background: Cancer-testis antigens (CTAs) have restricted expression in normal adult tissues but have been found to be overexpressed in multiple tumors.  This and their ability to elicit spontaneous cellular and humoral immune responses have rendered CTAs as...

Cancer testis antigen co-expression landscape in solid tumors

by OmniSeq Staff | Dec 3, 2020 | News

Abstract Background Cancer testis antigens (CTAs) are tumor antigens that have a highly tissue-restricted expression but are often expressed in diverse malignancies. With their highly immunogenic expression limited to tumor cells, CTAs have become a prime target for...

PD-L1 by RNA next generation sequencing: Comparison with PD-L1 IHC 22C3 and association with survival benefit from pembrolizumab with or without chemotherapy in non-small cell lung cancer

by OmniSeq Staff | Dec 3, 2020 | News

Yong Hee Lee, Grace Dy, Paul DePietro, Jeffrey Conroy, Sarabjot Pabla and Mary Nesline Abstract Background PD-L1 immunohistochemistry (IHC) testing is suboptimal for predicting patient clinical benefit for checkpoint inhibition, while PD-L1 liquid biopsy is not...

Complex markers of survival from pembrolizumab: the potential predictive role of tumor mutational burden (TMB) and KRAS

by OmniSeq Staff | Dec 2, 2020 | News

Yong Hee Lee, Carrie Hoefer, Paul DePietro and Mary Nesline Abstract Background Pembrolizumab, with or without chemotherapy, is NCCN guideline-recommended treatment for NSCLC cancer patients depending on tumor PD-L1 status by IHC. PD-L1 IHC provides guidance for...
« Older Entries

Follow Us on Twitter

OmniSeqFollow

Avatar
AvatarOmniSeq@OmniSeq·
15 Jun

LabCorp (LH) Boosts Precision Oncology With INSIGHT NGS Launch | NASDAQ https://www.nasdaq.com/articles/labcorp-lh-boosts-precision-oncology-with-insight-ngs-launch-2021-06-15

Reply on Twitter 1404816755453829127Retweet on Twitter 14048167554538291271Like on Twitter 14048167554538291274Twitter 1404816755453829127
Retweet on TwitterOmniSeq Retweeted
AvatarLabcorp@Labcorp·
10 Jun

Labcorp’s powering the next breakthrough with OmniSeq INSIGHT—launching today! Our new oncology test for all solid tumors. Learn more: https://bit.ly/3pDv7TG

Reply on Twitter 1403075776162013192Retweet on Twitter 14030757761620131926Like on Twitter 140307577616201319214Twitter 1403075776162013192
AvatarOmniSeq@OmniSeq·
10 Jun

Breaking news! @Labcorp and @OmniSeq launch OmniSeq Insight, a next-generation sequencing platform to advance precision #oncology by providing evidence-based, personalized treatment recommendations based on the genomic profiling of a patient’s solid tumor.
https://tinyurl.com/4a44vsn8

Reply on Twitter 1403000589517168649Retweet on Twitter 1403000589517168649Like on Twitter 14030005895171686494Twitter 1403000589517168649
Retweet on TwitterOmniSeq Retweeted
AvatarSarabjot Pabla@PablaSabi·
9 Jun

Great work by Dr. Marc Ernstoff, @YAbdouMD and team where @OmniSeq tumor immune profiling helps deepen our understanding of immunotoxicity to checkpoint inhibitors. https://twitter.com/YAbdouMD/status/1402432949774172165

Yara Abdou, MD@YAbdouMD

Increased TILs and high PDL-1 are associated with increased risk for immune related adverse events (p = 0.04 & 0.03 respectively)

#ASCO21 #Immunotherapy @OncoAlert @UNC_Lineberger @RoswellPark

Reply on Twitter 1402594085261688834Retweet on Twitter 14025940852616888342Like on Twitter 14025940852616888345Twitter 1402594085261688834
Retweet on TwitterOmniSeq Retweeted
AvatarSarabjot Pabla@PablaSabi·
5 Jun

We have a long way to go with integrative bio marker testing. Some like @OmniSeq are pioneering integrated genomic and immune profiling assays to have a more comprehensive understanding of the tumor immune micro-environment. https://twitter.com/LudaBazhenovaMD/status/1400881353315414019

LudaBazhenovaMD@LudaBazhenovaMD

We have to do better! @IASLC

Reply on Twitter 1400978005510574081Retweet on Twitter 14009780055105740811Like on Twitter 14009780055105740811Twitter 1400978005510574081
Load More...

  • Facebook
  • Twitter
©2021 OmniSeq Corporation | Privacy Practices and Terms of Use. Regulatory   .